Search
for

    Did you mean Androgen-Mediated Cutaneous Disorders?
    GlossaryAndrogen-Mediated Cutaneous Disorders

    skin conditions influenced by male hormones like testosterone

    Androgen-Mediated Cutaneous Disorders are skin conditions influenced by androgens, which are male hormones like testosterone. These disorders include acne, hirsutism (excessive hair growth), and androgenetic alopecia (pattern hair loss). They occur because androgens can affect the skin's oil production, hair growth, and hair loss patterns.

    Related Terms

    Learn

    5 / 801 results

      learn Osteopontin

      signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss

      learn Neem Oil

      natural substance from Neem tree with medicinal and pesticidal properties

      learn Fluridil

      a topical anti-androgen with less systemic involvement

    Research

    5 / 1000+ results

    Community Join

    5 / 1000+ results

      community Androgenetic alopecia is a skin disease: DHT-mediated skin disorders

      in Research/Science  65 upvotes 2 years ago
      Dihydrotestosterone (DHT) impacts various skin conditions, including Androgenetic alopecia and seborrheic dermatitis, by causing overactivity in sebaceous glands. Topical medications Tacrolimus and Clobetasol can reduce these inflammatory conditions, and treatments like RU58841, Minoxidil, and Finasteride may also be beneficial.

      community Mental Health and Finasteride Questions

      in General  162 upvotes 1 year ago
      A 20-year-old with anxiety and depression is considering finasteride for hair loss but is worried about potential side effects. They decide to consult a doctor and consider starting with a low dose, while also exploring topical finasteride as a potentially safer option.

      community EU Shouldn't Ban Fin & Dut: PFS is NOT REAL.

      in Research/Science  11 upvotes 1 year ago
      Finasteride and Dutasteride do not cause depression or "Post Finasteride Syndrome," with concerns often linked to the nocebo effect and preexisting mental health issues. The EU is unlikely to ban these drugs, but access may become more restricted due to ongoing debates.